Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + lenvatinib + etoposide + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Iparomlimab + tuvonralimab + lenvatinib + EP/EC is an investigational combination regimen being evaluated for the first-line treatment of unresectable or metastatic extrapulmonary neuroendocrine carcinoma (EP-NEC). The regimen's immunotherapy backbone, QL1706 (also known as Qibeian), is a bifunctional combination of two monoclonal antibodies: iparomlimab (targeting PD-1) and tuvonralimab (targeting CTLA-4) in a fixed 2:1 ratio. This is combined with lenvatinib, a multi-kinase inhibitor targeting VEGFR and FGFR, and standard platinum-etoposide chemotherapy (etoposide plus either cisplatin or carboplatin). The combination aims to enhance anti-tumor activity by simultaneously blocking multiple immune checkpoints, inhibiting angiogenesis and tumor cell proliferation, and inducing cytotoxic cell death.
- Brand names
- Qibeian
- Other names
- iparomlimab + tuvonralimab injection + lenvatinib + EP/ECQL1706 + lenvatinib + etoposide + platinum
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)TOP2A (DNA topoisomerase II)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + lenvatinib + etoposide + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + lenvatinib + etoposide + cisplatin + carboplatin.